Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market Analysis, Major Competiton and Strategies, Regional Outlook | F.Hoffmann-La Roche, Becton, Dickinson and Company

Methicillin Resistant Staphylococcus aureus (MRSA) is the most prevalent multi-drug resistant bacteria and a growing threat to health. The Centers for Disease Control and Prevention estimates that around 1 in 50 people in the U.S. carried MRSA in their noses as of August 2019. Furthermore, these individuals are four times more susceptible to infection. MRSA is commonly found in hospitals and healthcare facilities and it can cause severe health problems such as pneumonia, bloodstream infections, sepsis, and even death. The MRSA infection can be tested with the help of test kits, instruments, reagents and software. New DNA-based tests are fast, however they have proven to be cost-prohibitive for widespread use. Traditional methods rely on time-consuming culture techniques which require 48 hours to exclude MRSA and several days to confirm positives. However, these allow hospitals to affordably implement screening to help optimize patient outcomes and mitigate the risks associated with cross-contamination.

Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market - Competitive Landscape

Key players operating in the methicillin resistant Staphylococcus aureus (MRSA) testing systems market are F.Hoffmann-La Roche, Becton, Dickinson and Company, Hain Lifescience GmbH, BioMérieux, 3M Company, Bio-Rad Laboratories Inc., Abacus Diagnostica, Abbott Laboratories, Puritan Medical Products, Diatherix Eurofins, LLC, Arlington Scientific Inc., AdvanDx, Genspeed Biotech GmbH, Cepheid Inc., Luminex Corporation, and R-Biopharm AG.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/3803

The increasing prevalence of methicillin resistant staphylococcus aureus infection as well as approvals for products developed by market players are expected to drive growth of the methicillin resistant Staphylococcus aureus (MRSA) testing systems market.

The growing prevalence of methicillin resistant Staphylococcus aureus infection worldwide is expected to drive growth of the methicillin resistant Staphylococcus aureus (MRSA) testing systems market. According to the U.S. Department of Health and Human Services report of March 2019, nearly 120,000 staphylococcus aureus bloodstream infections and 20,000 associated deaths occurred in the U.S. in 2017. After years of slow progress, the rate of decline of MRSA bloodstream infections has slowed, but bloodstream infections caused by methicillin-susceptible S. aureus in hospitals are increasing day by day in the community.

Moreover, products approvals by regulatory bodies are expected to accelerate the Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems market growth in the near future. For instance, in October 2019, Luminex Corporation announced that the company has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the ARIES MRSA Assay. The assay is an integrated, real-time, polymerase chain reaction (PCR) based, qualitative, in vitro diagnostic test for the direct detection of methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs in patients at risk for nasal colonization. The Luminex ARIES System is a real-time instrument designed to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into the modern laboratory.

Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market - Restraints

However, growth of the methicillin resistant staphylococcus aureus (MRSA) testing systems market may be hampered owing to the increasing product recalls of methicillin resistant staphylococcus aureus (MRSA) testing systems in the market. For instance, in August 2019, the U.S. FDA initiated a product recall on Becton Dickinson & Company’s BD Max MRSA test kit because the foil bags containing extraction tubes for BD MAX Reagent products may not be sealed properly which can lead to false representation of test results. An advisory has been released to all the users of BD Max instruments within testing facilities to ensure awareness and prevent false test results.

Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market – Regional Analysis

North America accounted for the largest share in the methicillin resistant staphylococcus aureus (MRSA) testing systems market, in 2019 owing to the increasing number of mergers and acquisitions in the U.S. For instance, in April 2017, Avantor Performance Materials, LLC, announced the acquisition of Puritan Products, Inc., a supplier of cGMP buffers and solutions for Biopharma customers, and high-purity chemistries for Research and Electronic Materials customers. The acquisition of the Puritan Products brand expanded Avantor’s cGMP operations, improved supply chain security, and provided new teams experienced in high-purity materials manufacturing such as J.T.Baker, Macron Fine Chemicals, Puritan MRSA Transport Medium and Puritan brands of high-purity products and packaging for Avantor to become more agile and responsive to the needs of its customers.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/3803

Furthermore, major companies in the market are focusing on obtaining product approvals to gain commercial rights for the sale of their products in a particular country. This is expected to drive growth of the methicillin resistant staphylococcus aureus (MRSA) testing systems market in Europe. For instance, in January 2014, Roche announced the CE-IVD launch of the cobas MRSA/SA Test for the early, simultaneous detection of methicillin-resistant staphylococcus aureus (MRSA) and methicillin-sensitive staphylococcus aureus (SA) from nasal specimens. The cobas MRSA/SA test detects both organisms from a single specimen, providing accurate and reliable results for effective prevention and control of MRSA/SA infections. With an innovative design to include diverse geographical strain coverage, coupled with automation on the cobas 4800 System, the cobas MRSA/SA test can process specimens using a fast and advanced real-time polymerase chain reaction (PCR) amplification and detection available.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.